Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
- Author:
Junshik HONG
1
;
Yoo Jin LEE
;
Sung Hwa BAE
;
Jun Ho YI
;
Sungwoo PARK
;
Myung Hee CHANG
;
Young Hoon PARK
;
Shin Young HYUN
;
Joo-Seop CHUNG
;
Ji Eun JANG
;
Joo Young JUNG
;
So-Yeon JEON
;
Seo-Young SONG
;
Hawk KIM
;
Dae Sik KIM
;
Sung-Hyun KIM
;
Min Kyoung KIM
;
Sang Hoon HAN
;
Seonyang PARK
;
Yoo-Jin KIM
;
Je-Hwan LEE
;
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Blood Research 2021;56(2):102-108
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods:Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results:A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion:Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
